Ades F - Search Results

1

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart M. Ades F, et al. J Clin Oncol. 2014 Sep 1;32(25):2794-803. doi: 10.1200/JCO.2013.54.1870. Epub 2014 Jul 21. J Clin Oncol. 2014. PMID: 25049332 Review.

2

Controversial issues in early-stage breast cancer: a global collaborative survey, supported by the European Society for Medical Oncology (ESMO).

Zardavas D, Ades F, Spasojevic IB, Pugliano L, Capelan M, Paesmans M, de Azambuja E, Piccart M. Zardavas D, et al. Among authors: ades f. Ann Oncol. 2014 Aug;25(8):1558-62. doi: 10.1093/annonc/mdu093. Epub 2014 Feb 20. Ann Oncol. 2014. PMID: 24562450 Free article.

3

The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data.

Bozovic-Spasojevic I, Zardavas D, Brohée S, Ameye L, Fumagalli D, Ades F, de Azambuja E, Bareche Y, Piccart M, Paesmans M, Sotiriou C. Bozovic-Spasojevic I, et al. Among authors: ades f. Clin Cancer Res. 2017 Jun 1;23(11):2702-2712. doi: 10.1158/1078-0432.CCR-16-0979. Epub 2016 Nov 9. Clin Cancer Res. 2017. PMID: 28151718

4

Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.

Ades F, Senterre C, de Azambuja E, Sullivan R, Popescu R, Parent F, Piccart M. Ades F, et al. Ann Oncol. 2013 Nov;24(11):2897-902. doi: 10.1093/annonc/mdt352. Epub 2013 Sep 28. Ann Oncol. 2013. PMID: 24078620 Free article.

5

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).

Ades F, de Azambuja E, Daugaard G, Ameye L, Moulin C, Paesmans M, De Jong D, Decoster L, De Greve J, Ismael G, Møller AK, Piccart M, Awada A. Ades F, et al. J Chemother. 2013 Aug;25(4):239-46. doi: 10.1179/1973947813Y.0000000085. J Chemother. 2013. PMID: 23906077

6

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M. Pinto AC, et al. Among authors: ades f. Breast. 2013 Aug;22 Suppl 2:S152-5. doi: 10.1016/j.breast.2013.07.029. Breast. 2013. PMID: 24074778 Free article. Review.

7

Clinical practice-changing trials: the HERA study paradigm.

Zardavas D, Ades F, de Azambuja E. Zardavas D, et al. Among authors: ades f. Expert Rev Anticancer Ther. 2013 Nov;13(11):1249-56. doi: 10.1586/14737140.2013.848168. Epub 2013 Oct 21. Expert Rev Anticancer Ther. 2013. PMID: 24138446 Review.

8

Cardiotoxicity of systemic agents used in breast cancer.

Ades F, Zardavas D, Pinto AC, Criscitiello C, Aftimos P, de Azambuja E. Ades F, et al. Breast. 2014 Aug;23(4):317-28. doi: 10.1016/j.breast.2014.04.002. Epub 2014 May 1. Breast. 2014. PMID: 24794210 Free article. Review.

9

Anticancer drug development: moving away from the old habits.

Ades F, Zardavas D, Aftimos P, Awada A. Ades F, et al. Curr Opin Oncol. 2014 May;26(3):334-9. doi: 10.1097/CCO.0000000000000076. Curr Opin Oncol. 2014. PMID: 24614094 No abstract available.

10

An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.

Ades F, Senterre C, Zardavas D, de Azambuja E, Popescu R, Parent F, Piccart M. Ades F, et al. Eur J Cancer. 2014 Dec;50(18):3089-97. doi: 10.1016/j.ejca.2014.09.011. Epub 2014 Oct 19. Eur J Cancer. 2014. PMID: 25446375

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page